Markets:

Overview

News

Currencies

International

Treasuries

Disc Medicine, Inc. - Common Stock (NQ:IRON)

78.34 -0.50 (-0.63%)

Streaming Delayed Price Updated: 11:11 AM EDT, Aug 21, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Disc Medicine, Inc. - Common Stock

< Previous 1 2 3 Next >

Disc Medicine Eyes Mid-2026 Bitopertin Approval as EPP Trial Demand Surges ↗

May 26, 2026

Disc Medicine (NASDAQ:IRON) Chief Executive Officer John Quisel said patient demand for the company’s bitopertin program in erythropoietic protoporphyria, or EPP, remains strong after the company...

Via MarketBeat

Disc Medicine Insider Sells $380K in Stock Amid 70% One-Year Surge ↗

April 21, 2026

Disc Medicine advances therapies for serious blood disorders; a key insider recently trimmed their stake amid strong one-year share gains.

Via The Motley Fool

Topics Regulatory Compliance

Disc Medicine CFO Sells $720k Worth of Shares Amid FDA Rejection ↗

March 01, 2026

This clinical-stage biopharmaceutical company recently had one of its treatments rejected for FDA approval. Now the company is cutting its workforce.

Via The Motley Fool

Topics Regulatory Compliance

Disc Medicine, Sanofi, Eli Lilly Shares Slip On Reports Of FDA Increasing Review Time For Drugs Granted Priority Review Vouchers ↗

January 15, 2026

Via Stocktwits

Disc Medicine Stock Is Swinging, but This Fund's New $52 Million Bet Shows Conviction ↗

February 25, 2026

Disc Medicine develops therapies for rare blood disorders, leveraging clinical-stage biotech expertise in red blood cell biology.

Via The Motley Fool

Topics Regulatory Compliance

Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million ↗

February 25, 2026

This biotech specializes in monoclonal antibody therapies for inflammatory and immunological diseases with significant unmet needs.

Via The Motley Fool

Topics Regulatory Compliance

This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges ↗

February 25, 2026

RAPT Therapeutics develops oral therapies for oncology and inflammatory diseases, with lead candidates progressing in clinical trials.

Via The Motley Fool

Topics Regulatory Compliance

Disc Medicine Lands New $20 Million Investment as FDA Sets Up Potential Q4 Catalyst ↗

February 25, 2026

This clinical-stage biotech develops therapies targeting hematologic disorders, with a pipeline centered on red blood cell biology.

Via The Motley Fool

Topics Regulatory Compliance

Disc Medicine Stock Slumps After FDA Declines Approval For Inherited Disorder Drug Over Efficacy Concerns ↗

February 13, 2026

The FDA said in a letter to the company published on Friday that the data submitted by the company is insufficient proof of clinical benefit for bitopertin.

Via Stocktwits

What Investors Should Know About a $511K Disc Medicine Insider Sale and a 26% Stock Run ↗

January 11, 2026

This clinical-stage biotech specializing in blood disorders reported a notable insider sale amid strong recent stock performance.

Via The Motley Fool

Topics Regulatory Compliance

Disc Medicine Stock Slides After FDA Fast-Track Approval Doubts Surface — Wall Street Calls It An ‘Overreaction’ ↗

December 19, 2025

Stat News on Friday raised concerns for Biopertin’s expedited approval under the FDA Commissioner's National Priority Voucher program.

Via Stocktwits

Portfolio Adjustment: Institutional Heavyweight Exits Biotech Stock ↗

November 19, 2025

Bain Capital completely exited its position in Disc Medicine stock during the third quarter

Via The Motley Fool

Disc Medicine Inc (NASDAQ:IRON) Reports Wider-Than-Expected Q3 2025 Loss Amid Pipeline Advancements ↗

November 06, 2025

Disc Medicine reported a wider Q3 2025 loss but advanced its bitopertin NDA with FDA priority review, targeting a 2025/2026 launch.

Via Chartmill

Top stock movements in today's session. ↗

October 17, 2025

Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

Gold Falls 1%; SLB Posts Better-Than-Expected Q3 Earnings ↗

October 17, 2025

Via Benzinga

Revolution Medicines, Disc Medicine, American Express And Other Big Stocks Moving Higher On Friday ↗

October 17, 2025

Via Benzinga

Which stocks are gapping on Friday? ↗

October 17, 2025

Traders are paying attention to the gapping stocks in Friday's session. Let's dive into which stocks are experiencing notable gaps.

Via Chartmill

The FDA Just Granted Its Speediest Review Ever. Disc Medicine, Others Fly. ↗

October 17, 2025

The Commissioner's National Priority Review vouchers aims to speed up the review process to just one to two months.

Via Investor's Business Daily

FDA Unveils First Experimental Drugs Under Fast-Track Voucher Plan To Cut Drug Review Times ↗

October 17, 2025

The FDA launched a new voucher program to fast-track reviews, naming nine experimental drugs for cancer, diabetes, addiction, and other conditions.

Via Benzinga

Discover the top movers in Friday's pre-market session. ↗

October 17, 2025

Before the US market kicks off on Friday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

Via Chartmill

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

October 17, 2025

Via Benzinga

Revolution Medicines, Disc Medicine, Regeneron Stocks Jump After-Hours As FDA Fast-Tracks 9 Drugs Under New Review Program ↗

October 17, 2025

The FDA’s new National Priority Voucher pilot helps with faster drug reviews, cutting timelines from nearly a year to weeks.

Via Stocktwits

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

October 16, 2025

Via Benzinga

Market Momentum: A Diverse Group of Stocks Soar to 52-Week Highs Amidst Shifting Tides

October 14, 2025

As of mid-October 2025, a compelling and diverse group of companies, spanning utilities, biotechnology, advanced materials, and defense, have seen their stocks reach impressive 52-week highs. This...

Via MarketMinute

Topics Earnings Economy Intellectual Property

Disc Medicine (IRON) Q2 Loss Widens 109% ↗

August 07, 2025

Via The Motley Fool

10 Health Care Stocks With Whale Alerts In Today's Session ↗

April 01, 2025

Via Benzinga

Progress Software, Disc Medicine And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

January 22, 2025

Via Benzinga

Integra LifeSciences Posts Upbeat Results, Joins Air Transport Services, Freshpet, Yum China And Other Big Stocks Moving Higher On Monday ↗

November 04, 2024

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

November 04, 2024

Via Benzinga

IRON Stock Earnings: Disc Medicine Beats EPS for Q2 2024 ↗

August 08, 2024

IRON stock results show that Disc Medicine beat analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Disc Medicine, Inc. - Common Stock (NQ:IRON)

Headline News about Disc Medicine, Inc. - Common Stock

Starting at /week.